Eric Halioua

Eric Halioua

Company: PDC*line Pharma

Job title: President & Chief Executive Officer


New Class of Antigen-Specific Cancer Active Immunotherapies based on an Off-the-Shelf Antigen Presenting Cell line (PDC*line) 1:30 pm

PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors Applying the technology for any cancerRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.